STOCK TITAN

Vanguard reports 0 shares of Elanco after realignment (NYSE: ELAN)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Elanco Animal Health Inc amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares of Elanco common stock. The filing states that Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The form is signed by Ashley Grim on 03/26/2026.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did The Vanguard Group report for ELAN in this Schedule 13G/A?

The Vanguard Group reported 0 shares of Elanco Animal Health Inc. The filing states Vanguard now reports certain subsidiaries separately following an internal realignment on January 12, 2026.

Why does Vanguard show zero beneficial ownership for ELAN?

Vanguard explains an internal realignment on January 12, 2026, after which subsidiaries or business divisions report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Who signed the Schedule 13G/A amendment for ELAN?

The filing is signed by Ashley Grim, Head of Global Fund Administration. The signature date on the form is 03/26/2026.

Does the filing identify any party with more than 5% of ELAN shares?

The Schedule states no other person's interest reported here exceeds 5%. It notes Vanguard-managed accounts and investment companies are included in the reporting structure.

What address is listed for The Vanguard Group in the ELAN filing?

The filing lists The Vanguard Group's address as 100 Vanguard Blvd., Malvern, PA, 19355. The issuer address for Elanco is listed as 2500 Innovation Way, Greenfield, IN, 46140.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026